Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › LGND

RICE HALL JAMES & ASSOCIATES, LLC position in LGND

LIGAND PHARMACEUTICALS INC · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 223,908 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$69.9M, representing 3.71% of its reported portfolio and ranking #1 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)223.91K sh
Reported value held$69.94M
Portfolio Weight3.71%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's LGND position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in LGND in Q3 2023 at 282,961 shares (US$17.0M). The position peaked in Q2 2026 at 270,052 shares, worth US$85.4M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 223,908 shares valued at US$69.9M — a reduction of -46,144 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 282.96K $16.96M New
Q4 2023 276.01K $19.71M Reduce
Q1 2024 279.78K $20.45M Add
Q2 2024 292.48K $24.64M Add
Q3 2024 312.88K $31.32M Add
Q4 2024 304.93K $32.67M Reduce
Q1 2025 297.22K $31.25M Reduce
Q2 2025 337.35K $38.35M Add
Q3 2025 294.49K $52.17M Reduce
Q4 2025 279.63K $52.87M Reduce
Q1 2026 283.57K $56.61M Add
Q2 2026 270.05K $85.36M Reduce
Q3 2026 223.91K $69.94M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LGND and 13F data

LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$139.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LGND

All LGND fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held LGND?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed LGND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in LGND?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 223.91K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $69.94M, representing 3.71% of its reported portfolio and ranking #1.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling LGND?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in LGND. The position peaked in Q2 2026 at 270.05K shares.

Which other funds hold LGND?

Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.